SG11202013062VA - Sulfonimidamide compounds as inhibitors of interleukin-1 activity - Google Patents
Sulfonimidamide compounds as inhibitors of interleukin-1 activityInfo
- Publication number
- SG11202013062VA SG11202013062VA SG11202013062VA SG11202013062VA SG11202013062VA SG 11202013062V A SG11202013062V A SG 11202013062VA SG 11202013062V A SG11202013062V A SG 11202013062VA SG 11202013062V A SG11202013062V A SG 11202013062VA SG 11202013062V A SG11202013062V A SG 11202013062VA
- Authority
- SG
- Singapore
- Prior art keywords
- interleukin
- inhibitors
- activity
- sulfonimidamide
- compounds
- Prior art date
Links
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701313P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042711 WO2020018975A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202013062VA true SG11202013062VA (en) | 2021-02-25 |
Family
ID=67659954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013062VA SG11202013062VA (en) | 2018-07-20 | 2019-07-19 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12234245B2 (en) |
| EP (1) | EP3823974A1 (en) |
| JP (1) | JP7320595B2 (en) |
| KR (1) | KR20210034596A (en) |
| CN (1) | CN112513048A (en) |
| AR (1) | AR115822A1 (en) |
| AU (1) | AU2019306658A1 (en) |
| BR (1) | BR112021001044A2 (en) |
| CA (1) | CA3105521A1 (en) |
| CL (1) | CL2021000153A1 (en) |
| CO (1) | CO2021001530A2 (en) |
| CR (1) | CR20210022A (en) |
| IL (1) | IL279256A (en) |
| MA (1) | MA53172A (en) |
| MX (1) | MX2021000780A (en) |
| PE (1) | PE20211811A1 (en) |
| PH (1) | PH12021500005A1 (en) |
| SG (1) | SG11202013062VA (en) |
| TW (1) | TWI825134B (en) |
| UA (1) | UA128558C2 (en) |
| WO (1) | WO2020018975A1 (en) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| SI3658539T1 (en) | 2017-07-24 | 2024-06-28 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2019068772A1 (en) | 2017-10-03 | 2019-04-11 | Inflazome Limited | Novel compounds |
| KR20210034596A (en) | 2018-07-20 | 2021-03-30 | 에프. 호프만-라 로슈 아게 | Sulfonimideamide compounds as inhibitors of interleukin-1 activity |
| PE20211049A1 (en) | 2018-07-20 | 2021-06-04 | Hoffmann La Roche | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN 1 ACTIVITY |
| PH12021500025A1 (en) * | 2018-11-13 | 2022-05-02 | Novartis Ag | Compound and compositions for treating conditions associated with nlrp activity |
| ES2974842T3 (en) | 2018-11-13 | 2024-07-01 | Novartis Ag | Compounds and compositions for the treatment of conditions associated with nlrp activity |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| JP2022507506A (en) * | 2018-11-16 | 2022-01-18 | ノバルティス アーゲー | Compounds and compositions for treating conditions associated with NLRP activity |
| US20230063462A1 (en) * | 2019-01-23 | 2023-03-02 | Novartis Ag | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| WO2020254697A1 (en) | 2019-06-21 | 2020-12-24 | Ac Immune Sa | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| WO2021009567A1 (en) | 2019-07-17 | 2021-01-21 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| EP3999496B1 (en) | 2019-07-17 | 2024-12-18 | Zomagen Biosciences Ltd | N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as nlpr3 modulators for the treatment of multiple sclerosis (ms) |
| KR102797670B1 (en) * | 2019-11-12 | 2025-04-18 | 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. | Amide derivatives and their preparation methods and medical applications |
| CN115461120A (en) * | 2020-01-22 | 2022-12-09 | 豪夫迈·罗氏有限公司 | Sulfonylimide amide compounds as NLRP3 modulators |
| KR20220154165A (en) * | 2020-03-16 | 2022-11-21 | 조마젠 바이오사이언시즈 엘티디 | NLRP3 modulator |
| CN115485026A (en) | 2020-04-15 | 2022-12-16 | 詹森药业有限公司 | NLRP3 Inflammatory Pathway Inhibitor Pyrazolo[1,2-D][1,2,4]triazin-2-yl-acetamide |
| AU2021257619A1 (en) | 2020-04-15 | 2022-12-15 | Janssen Pharmaceutica Nv | Pyrazolo[1,5-d][1,2,4]triazine-5(4H)-acetamides as inhibitors of the NLRP3 inflammasome pathway |
| BR112022020798A2 (en) | 2020-04-23 | 2022-11-29 | Janssen Pharmaceutica Nv | TRICYCLIC COMPOUNDS AS NLRP3 INHIBITORS |
| BR112022021881A2 (en) | 2020-04-30 | 2022-12-20 | Janssen Pharmaceutica Nv | NEW TRIAZINOINDOL COMPOUNDS |
| CN115667225A (en) | 2020-05-28 | 2023-01-31 | 詹森药业有限公司 | Compound (I) |
| BR112022025612A2 (en) | 2020-06-19 | 2023-01-17 | Ac Immune Sa | DIHYDRO-OXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMASOMA PATHWAY |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| CN116194445A (en) | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | New compounds |
| CN114539256B (en) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | Tricyclic compounds and medical uses thereof |
| US20240174670A1 (en) | 2021-03-04 | 2024-05-30 | Janssen Pharmaceutica Nv | 4-amino-6-oxo-pyridazine derivatives modulating nlrp3 |
| EP4301753A1 (en) | 2021-03-04 | 2024-01-10 | Janssen Pharmaceutica NV | 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3 |
| JP2024515817A (en) | 2021-04-29 | 2024-04-10 | ヤンセン ファーマシューティカ エヌ．ベー． | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| CN116917282A (en) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | Amide derivatives and their applications |
| WO2022237782A1 (en) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | Amide derivative and application thereof |
| MX2023014891A (en) | 2021-07-01 | 2024-02-12 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides. |
| IL308461A (en) * | 2021-07-19 | 2024-01-01 | Genentech Inc | Sulfonimidamide compounds and their uses |
| CN115894478B (en) * | 2021-09-30 | 2025-04-04 | 杭州民生药物研究院有限公司 | A novel pyridopyrazole heterocyclic compound and its application |
| CN118541366A (en) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | Dihydrooxazole derivative compounds |
| CN116804018A (en) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | Amide derivatives, preparation methods and applications in medicine |
| CN117247393A (en) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | Amide derivatives, preparation methods and applications in medicine |
| EP4551549A1 (en) * | 2022-07-06 | 2025-05-14 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| KR20250036233A (en) | 2022-07-14 | 2025-03-13 | 에이씨 이뮨 에스에이 | Pyrrolotriazine and imidazotriazine derivatives as modulators of the NLRP3 inflammasome pathway |
| JP2025526423A (en) | 2022-07-28 | 2025-08-13 | エーシー・イミューン・エス・アー | new compound |
| AU2023347443A1 (en) | 2022-09-23 | 2025-04-03 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
| WO2024249539A1 (en) | 2023-06-02 | 2024-12-05 | Merck Sharp & Dohme Llc | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| WO2025101716A1 (en) * | 2023-11-07 | 2025-05-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Processes for synthesis of trifunctionalized sulfur(vi) compounds |
| TW202535370A (en) | 2023-12-14 | 2025-09-16 | 美商默沙東有限責任公司 | Indazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| WO2025128781A1 (en) | 2023-12-14 | 2025-06-19 | Merck Sharp & Dohme Llc | Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| US20250326772A1 (en) | 2024-04-19 | 2025-10-23 | Kyorin Pharmaceutical Co., Ltd. | Mrgprx2 antagonists, pharmaceutical composition including mrgprx2 antagonist, and method of treating mrgprx2-mediated disease or disorder |
| CN119100956B (en) * | 2024-09-03 | 2025-12-02 | 大连理工大学 | A catalyst-free, light-driven method for the synthesis of sulfinamide compounds |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| DE19540995A1 (en) | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituted sulfonimidamides, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
| EP0964849B1 (en) | 1997-01-29 | 2003-06-04 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| WO2001019390A1 (en) | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| BR0214810A (en) | 2001-11-30 | 2004-11-03 | Pfizer Prod Inc | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation. |
| MX341482B (en) | 2010-02-22 | 2016-08-22 | Raqualia Pharma Inc | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases. |
| CN104023729A (en) | 2011-09-02 | 2014-09-03 | 协和发酵麒麟株式会社 | Chemokine receptor activity regulator |
| BR112015029240A2 (en) | 2013-05-21 | 2017-07-25 | Univ Virginia Commonwealth | compound, composition and method of preventing or treating inflammation associated with inflammasome nrlp3 in an individual |
| AU2016222278B2 (en) * | 2015-02-16 | 2020-07-09 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
| FR3046933B1 (en) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS |
| JP2019512009A (en) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | Sulfonylurea and related compounds and uses thereof |
| ES2855732T3 (en) | 2016-04-18 | 2021-09-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES2940611T3 (en) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compounds and compositions for the treatment of conditions associated with NLRP activity |
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| BR112019024831A2 (en) | 2017-05-24 | 2020-06-09 | The University Of Queensland | compound, salt, solvate or prodrug, pharmaceutical composition, method of treating or preventing a disease, method of inhibiting nlrp3 |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| LT3661925T (en) | 2017-07-07 | 2022-03-10 | Inflazome Limited | NEW SULPHONAMIDE CARBOXAMIDE COMPOUNDS |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| SI3658539T1 (en) | 2017-07-24 | 2024-06-28 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| MA49901A (en) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | NEW SULFONAMIDE CARBOXAMIDE COMPOUNDS |
| BR112020002906A2 (en) | 2017-08-15 | 2020-08-04 | Inflazome Limited | new sulfonamide-carboxamide compounds |
| EP3668862A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CA3071150A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| TW201910317A (en) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | Novel compound |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | Novel substituted sulfonylurea derivatives |
| WO2019068772A1 (en) * | 2017-10-03 | 2019-04-11 | Inflazome Limited | Novel compounds |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| RU2020115098A (en) | 2017-11-09 | 2021-12-10 | Инфлазоум Лимитед | COMPOUNDS OF NEW SULFONAMIDE CARBOXAMIDES |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| WO2020010118A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
| WO2020010143A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Nlrp modulators |
| KR20210034596A (en) | 2018-07-20 | 2021-03-30 | 에프. 호프만-라 로슈 아게 | Sulfonimideamide compounds as inhibitors of interleukin-1 activity |
| PE20211049A1 (en) | 2018-07-20 | 2021-06-04 | Hoffmann La Roche | SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN 1 ACTIVITY |
| TWI811400B (en) | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | Further substituted triazolo quinoxaline derivatives |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| US12187702B2 (en) | 2018-08-15 | 2025-01-07 | Inflazome Limited | Sulfonamideurea compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (en) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Compounds and compositions for treating conditions associated with NLRP activity |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| PH12021500025A1 (en) | 2018-11-13 | 2022-05-02 | Novartis Ag | Compound and compositions for treating conditions associated with nlrp activity |
| JP2022507506A (en) | 2018-11-16 | 2022-01-18 | ノバルティス アーゲー | Compounds and compositions for treating conditions associated with NLRP activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| EP3914583A1 (en) | 2019-01-22 | 2021-12-01 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| US20230063462A1 (en) | 2019-01-23 | 2023-03-02 | Novartis Ag | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| PH12021552363A1 (en) | 2019-03-29 | 2022-09-05 | Medimmune Ltd | Compounds and conjugates thereof |
| WO2020254697A1 (en) | 2019-06-21 | 2020-12-24 | Ac Immune Sa | Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| IL293962B2 (en) | 2019-12-19 | 2025-10-01 | Jacobio Pharmaceuticals Co Ltd | Kras mutant protein inhibitors |
| CN115461120A (en) | 2020-01-22 | 2022-12-09 | 豪夫迈·罗氏有限公司 | Sulfonylimide amide compounds as NLRP3 modulators |
| TWI785474B (en) | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | Novel heterocyclic compounds useful as selective aurora a inhibitors |
| AR121078A1 (en) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | ARILAMIDE DERIVATIVES WITH ANTI-TUMOR ACTIVITY |
| KR20220132552A (en) | 2020-01-29 | 2022-09-30 | 유니버시다드 데 레스 일레스 발레아르스 | Metabolites of alpha-hydroxylated fatty acids, their medical uses and their use as biomarkers |
| BR112022020798A2 (en) | 2020-04-23 | 2022-11-29 | Janssen Pharmaceutica Nv | TRICYCLIC COMPOUNDS AS NLRP3 INHIBITORS |
| BR112022021881A2 (en) | 2020-04-30 | 2022-12-20 | Janssen Pharmaceutica Nv | NEW TRIAZINOINDOL COMPOUNDS |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| CN115667225A (en) | 2020-05-28 | 2023-01-31 | 詹森药业有限公司 | Compound (I) |
| BR112022025612A2 (en) | 2020-06-19 | 2023-01-17 | Ac Immune Sa | DIHYDRO-OXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMASOMA PATHWAY |
| IL277528B (en) | 2020-09-22 | 2022-05-01 | Ag Plenus Ltd | Herbicidal compounds and methods of use thereof |
| CN116194445A (en) | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | New compounds |
| EP4301753A1 (en) | 2021-03-04 | 2024-01-10 | Janssen Pharmaceutica NV | 4-alkoxy-6-oxo-pyridazine derivatives modulating nlrp3 |
| JP2024515817A (en) | 2021-04-29 | 2024-04-10 | ヤンセン ファーマシューティカ エヌ．ベー． | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| CN116917282A (en) | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | Amide derivatives and their applications |
| MX2023014891A (en) | 2021-07-01 | 2024-02-12 | Janssen Pharmaceutica Nv | 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides. |
-
2019
- 2019-07-19 KR KR1020217002210A patent/KR20210034596A/en not_active Withdrawn
- 2019-07-19 MX MX2021000780A patent/MX2021000780A/en unknown
- 2019-07-19 MA MA053172A patent/MA53172A/en unknown
- 2019-07-19 CA CA3105521A patent/CA3105521A1/en active Pending
- 2019-07-19 CN CN201980048375.6A patent/CN112513048A/en active Pending
- 2019-07-19 PE PE2021000082A patent/PE20211811A1/en unknown
- 2019-07-19 UA UAA202100695A patent/UA128558C2/en unknown
- 2019-07-19 CR CR20210022A patent/CR20210022A/en unknown
- 2019-07-19 BR BR112021001044-0A patent/BR112021001044A2/en unknown
- 2019-07-19 EP EP19753515.6A patent/EP3823974A1/en active Pending
- 2019-07-19 SG SG11202013062VA patent/SG11202013062VA/en unknown
- 2019-07-19 JP JP2021502987A patent/JP7320595B2/en active Active
- 2019-07-19 WO PCT/US2019/042711 patent/WO2020018975A1/en not_active Ceased
- 2019-07-19 AU AU2019306658A patent/AU2019306658A1/en not_active Abandoned
- 2019-07-22 TW TW108125886A patent/TWI825134B/en not_active IP Right Cessation
- 2019-07-22 AR ARP190102055A patent/AR115822A1/en not_active Application Discontinuation
-
2020
- 2020-12-07 IL IL279256A patent/IL279256A/en unknown
-
2021
- 2021-01-15 US US17/150,349 patent/US12234245B2/en active Active
- 2021-01-19 CL CL2021000153A patent/CL2021000153A1/en unknown
- 2021-01-19 PH PH12021500005A patent/PH12021500005A1/en unknown
- 2021-02-10 CO CONC2021/0001530A patent/CO2021001530A2/en unknown
-
2024
- 2024-12-19 US US18/988,433 patent/US20250115618A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UA128558C2 (en) | 2024-08-14 |
| US20210253596A1 (en) | 2021-08-19 |
| US20250115618A1 (en) | 2025-04-10 |
| TWI825134B (en) | 2023-12-11 |
| AR115822A1 (en) | 2021-03-03 |
| US12234245B2 (en) | 2025-02-25 |
| PE20211811A1 (en) | 2021-09-14 |
| BR112021001044A2 (en) | 2021-04-13 |
| WO2020018975A1 (en) | 2020-01-23 |
| MA53172A (en) | 2021-05-26 |
| KR20210034596A (en) | 2021-03-30 |
| AU2019306658A1 (en) | 2021-01-07 |
| PH12021500005A1 (en) | 2021-09-13 |
| CN112513048A (en) | 2021-03-16 |
| CR20210022A (en) | 2021-02-18 |
| TW202016078A (en) | 2020-05-01 |
| CL2021000153A1 (en) | 2021-07-09 |
| CA3105521A1 (en) | 2020-01-23 |
| MX2021000780A (en) | 2021-03-31 |
| JP7320595B2 (en) | 2023-08-03 |
| IL279256A (en) | 2021-01-31 |
| EP3823974A1 (en) | 2021-05-26 |
| JP2021532101A (en) | 2021-11-25 |
| CO2021001530A2 (en) | 2021-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279256A (en) | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | |
| IL280139A (en) | Sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| IL267961A (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| SG11202103839UA (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| EP3268006A4 (en) | Pyrrolotriazine inhibitors of irak4 activity | |
| EP3268367B8 (en) | Carboxamide inhibitors of irak4 activity | |
| IL281939A (en) | Inhibitors of vap-1 | |
| EP3267996A4 (en) | Pyrazolopyrimidine inhibitors of irak4 activity | |
| EP3268004A4 (en) | Pyrrolopyridazine inhibitors of irak4 activity | |
| EP3906029A4 (en) | Inhibitors of menin-mll interaction | |
| IL290929A (en) | Substituted cyanopyrrolidines with activity as usp30 inhibitors | |
| EP3200787A4 (en) | Inhibitors of irak4 activity | |
| EP3200788A4 (en) | Inhibitors of irak4 activity | |
| EP3200789A4 (en) | Inhibitors of irak4 activity | |
| EP3200790A4 (en) | Inhibitors of irak4 activity | |
| ZA202106766B (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| IL281815A (en) | Inhibitors of vap-1 | |
| DK3681885T3 (en) | TETRAHYDRO-IMIDAZO-QUINOLINE COMPOUNDS AS CBP/P300 INHIBITORS | |
| IL276312A (en) | Use of alkoxypyrazoles as nitrification inhibitors | |
| IL289023A (en) | Bicyclic heterocyclic compounds as inhibitors ofbcdin3d activity | |
| PL3826983T3 (en) | Use of substituted 2-thiazolines as nitrification inhibitors | |
| EP3801525A4 (en) | Inhibitors of prolyl-trna-synthetase | |
| IL277869A (en) | Substituted propanamides as inhibitors of nucleases | |
| SI3424930T1 (en) | Crystal of compound having jak-inhibiting activity | |
| EP3294721A4 (en) | 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors |